

Keming Gao, M.D., Ph.D.

-Curriculum Vitae-
(04/20/2009 Revision)

Office Address: Mood Disorders Program
10524 Euclid Avenue
12th Floor
W.O. Walker Center
Cleveland, OH 44106

Telephone: 216/844-2865
Home: 440/333-5926
Fax: 216/844-2875
E-mail: kgao_2001@yahoo.com
Keming.gao@uhhospitals.org

Date and Place of Birth: November 10, 1959.
Weifang City, Shandong Province, P. R. China.

Nationality: US citizen since 12/2006

Education:

07/04 – 07/2006 Research Fellow
Bipolar Disorder Research Center
Mood Disorders Program, Director, Joseph Calabrese, M.D.
Department of Psychiatry
University Hospitals of Cleveland
Case Western Reserve University School of Medicine
Cleveland, Ohio

07/03 - 06/04 Chief Resident
Department of Psychiatry
MetroHealth Medical Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

07/00 - 06/04 Resident in Psychiatry
Department of Psychiatry
MetroHealth Medical Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

08/94 - 05/96 Postdoctoral Fellow

Department of Pharmacology and Therapeutics
Louisiana State University Medical Center-Shreveport
Shreveport, Louisiana

09/91 - 07/94

Ph.D.
Department of Physiology
Shanghai Medical University
Shanghai, P. R. China

03/94 - 04/94

International Brain Research Organization-
Croucher Foundation Visiting Fellow
Department of Anatomy
The Chinese University of Hong Kong
New Territory, Hong Kong

09/88 - 07/91

Master Degree of Science
Department of Physiology
Shanghai Medical University
Shanghai, P. R. China

09/80 - 07/85

M.D.
Weifang Medical College
Weifang City, Shandong Province, P. R. China.

Professional Experience:

08/06 -

Assistant Professor
Department of Psychiatry
University Hospitals Case Medical Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

05/96 - 05/00

Research Associate
Department of Neurobiology, Pharmacology, and Physiology
The University of Chicago
Chicago, Illinois

06/04 - present

Visiting Professor
Weifang Medical University
Weifang City, Shandong Province, P. R. China

07/91 - 07/94

Instructor
Department of Physiology
Shanghai Medical University
Shanghai, P. R. China

07/85 - 09/88

Instructor

Department of Physiology
Weifang Medical College
Weifang City, Shandong Province, P. R. China.

09/87 - 07/88

Course Director
Department of Physiology
Weifang Medical College
Weifang City, Shandong Province, P. R. China.

Other Clinical Experiences:

12/2002 – 06/2006 MDOD (moonlighting)
Northcoast Behavior Health System
Cleveland, OH.

01/2003 – 06/2006 Moonlighting Staff (Attending status since 07/2004)
Portage Path Psychiatric Emergency Services
Akron, OH.

12/2004 – 06/2006 Attending Physician
Children's Comprehensive Services (Foundation for Living)
Mansfield, OH

08/2006 – Present Attending Physician
Department of Psychiatry
University Hospitals Case Medical Center
Cleveland, OH

Licenses and Certifications:

6/1998 ECFG certificate, Educational Commission for Foreign
Medical Graduates.

07/2002 – present Medical License, State Medical Board of Ohio.

10/2002 – present DEA certificate, Drug Enforcement Administration.

06/2008 - Diplomat, American Board of Psychiatry and Neurology.

Committee Involvement:

04/93 Member, Organizing Committee
First National Conference for the Young Chinese Physiologists.
Chinese Association for Physiological Sciences
Beijing, P. R. China

12/2005 – present Member, Steering Committee
Developing Center for Interventions and Services Research
(DCISR, P20): Bipolar Disorders Across the Life Span
Case Western Reserve University School of Medicine
University Hospitals of Cleveland

12/2006 – Member, Resident Research Education Committee
Department of Psychiatry
Case Western Reserve University School of Medicine

University Hospitals Case Medical Center

- 9/2007 - Review Member, Medical Student Admission Committee
Case Western Reserve University School of Medicine
Interview and Evaluate Medical Student Candidates
- 12/2007 - Member, The Lepow Day Research Review Committee
Case Western Reserve University School of Medicine
Review abstracts submitted by medical students
- 3/2009 - Member, Pharmacy and Therapeutics Committee
University Hospitals Case Medical Center
- 6/2009 - Member of Quality and Patient Safety Committee
University Hospitals Case Medical Center
- 6/2009 - Member of Central Credentialing Committee
University Hospitals Case Medical Center

Community Service:

- 07/2005 - Ad hoc Lecturer of Medical Education Series
Cleveland Chinese Contemporary Cultural Association,
Cleveland, OH
- 10/2008 – Medical Advisor, Alliance of Mental Ill of Greater
Cleveland National Alliance the Mentally Ill, Cleveland,
Ohio

Scientific Review of Research Applications:

Ad Hoc Reviewer Medical Research Council of the United Kingdom (since 2006)

Consultation/Advisor Boards:

- 09/2008 - Schering-Plough Research Institute
Kenilworth, New Jersey

Honors and Awards:

- 2008 Recipient of the travel award of the Tenth Annual “Future
Leaders in Psychiatry” meeting Sponsored by the
Department of Psychiatry and Behavioral Sciences at Emory
University School of Medicine, May 22-25, 2008, Orlando,
Florida.

- 2008 John C. and Sally S. Morley Family Foundation Award
“Quetiapine-XR Monotherapy in the Treatment of Major Depressive Disorder with Comorbid Generalized Anxiety Disorder.”
- 2006 Recipient of the travel award of the Eighth Annual “Future Leaders in Psychiatry” meeting Sponsored by the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, May 4-7, 2006, Miami, Florida.
- 2006 Recipient of American Psychiatric Association Research Colloquium for Junior Investigators, May 21, 2006, Toronto, Ontario Canada
- 2006 Recipient of the Second Annual Career Development Institute for Bipolar Disorder Award:
A Workshop on Launching and Maintaining a Career in Mental Health Research in Bipolar Disorder
Sponsored by the University of Pittsburgh and the NIMH
April 29 – May 2, 2006, Boca Raton, Florida.
- 2005 Recipient of the NIMH 45th NCDEU New Investigator Award, June 6-9, 2005, Boca Raton, Florida
- 2005 Recipient of American Psychiatric Association Research Colloquium for Junior Investigators, May 22, 2005, Atlanta, Georgia
- 2005 Recipient of Fellowship Travel Award of the 4th Annual Workshop on Clinical Trials in Psychopharmacology
Sponsored by The American Society of Clinical Psychopharmacology, NIMH, and the Zucker Hillside Hospital, April 12-14, 2005, New York City, NY
- 2003 Recipient of APA/Lilly Chief Resident Executive Leadership Program Travel Award, October 29-30, 2003, Boston, MA
- 08/94 - 05/96 Honorary Member
Department of Pharmacology and Therapeutics
Louisiana State University Medical Center-Shreveport
Shreveport, Louisiana
- 09/91 - 07/94 Ph.D. Student Representative, Class 1994

- Shanghai Medical University
Shanghai, P. R. China
- 1993 Recipient of "Shu Ping" Scholarship (First Scholarship in the history of modern China)
Shanghai "Shu Ping" Scholarship Foundation
Shanghai, P. R. China
- 1993 Excellent Physiology Academic Paper Award
Third National Conference for Young Chinese Physiologists
Zhang Xijun Foundation of the Chinese Association for Physiological Sciences
Beijing, P. R. China
- 1992 Third Place, Young Teacher Research Award
Shanghai Medical University
Shanghai, P. R. China
- 1992 Recipient of Excellence Scholarship of Chinese Education Ministry
Shanghai Medical University
Shanghai, P. R. China
- 9/88 - 7/91 M.S. Student Representative, Class 91 #1
Shanghai Medical University
Shanghai, P. R. China.
- 1991 Second Place, Graduate Student Academic Report Award
Shanghai Medical University
Shanghai, P. R. China
- 1990 Recipient of "Guang Hua" Scholarship
Shanghai Medical University
Shanghai, P. R. China
- 9/80 - 7/85 Academic Representative, Class 1985 #5
Weifang Medical College
Weifang City, Shandong Province, P. R. China
- 1985 Excellent Student of the Year
Weifang Medical College
Weifang City, Shandong Province, P. R. China
- 1984 Excellent Student of the Year
Weifang Medical College
Weifang City, Shandong Province, P. R. China
- 1982 Excellent Student of the Year

Weifang Medical College
Weifang City, Shandong Province, P. R. China

1981 Excellent Student of the Year
Weifang Medical College
Weifang City, Shandong Province, P. R. China

Press or Media Interview:

9/2005 Neuropsychiatry Review (by Timothy Begany)
Atypical Antipsychotics – First-line Therapies for Bipolar
Depression

11/25/2005 Medwire News
Atypical antipsychotics show bipolar depression promise

10/2006 Reuters Health (by Michelle Rizzo)
Antipsychotic deemed effective for anxiety disorder

10/27/2007 ABC News Health (by Michelle Rizzo)
Antipsychotic deemed effective for anxiety disorder

2/2007 Pharmacy Times (by Susan Farley)
Anxiety Disorders Helped by Antipsychotics

05/21/2007 APA News Release
Predictors of hospitalization and suicide attempts inpatients
with rapid cycling bipolar disorder.

4/2008 American Psychiatric News (by Rosemary Frei)
on “Antipsychotic Tested in Major Depressive Disorder.

5/2008 MedPage Today (by John Gever)
Antipsychotic Side Effects More Common in Patients with
Bipolar Disorder

8/2008 MedWire News (by Liam Davenport)
GAD and PD increased in bipolar I disorder in the presence
of SUD history

7/21/2009 Bipolar Magazine (by Michelle D. Roberts)
Bipolar disorder and substance use disorder (Dual
Diagnosis).

7/27/2009 Pharmawire of Financial Times Group (by Klara Czobor)

Sarcado-Loxapine in Development for the Treatment of
Bipolar Disorder

Professional Affiliations:

Member of American Society of Clinical Psychopharmacology (2005 - 2008)
Regular Member of the Society for Neuroscience (1997-).
Member of International Brain Research Organization (1997 -).
Member-in-training, Ohio Psychiatric Association (2001 - 2006).
Regular Member, Ohio Psychiatric Association (2006 -
Member-in-training, American Psychiatric Association (2001 - 2006).
Regular Member, American Psychiatric Association (2006 -
Member-in-training, American Medical Association (2003- 2005).
Member of the International Society for Bipolar Disorder (2006 -)
Member of the Anxiety Disorder Association of America (2009 -).

Referee for Journals:

Arch Gen Psychiatry with Dr. Calabrese (since 2009)
Biological Psychiatry with Dr. Calabrese (since 2007)
Bipolar Disorders with Dr. Calabrese (since 2007)
CNS Drugs with Dr. Calabrese (since 6/2008)
Cochrane Reviews (since 2007)
Depression and Anxiety (since 2006)
European Psychiatry (since August, 2009)
Expert Opinion on Drug Safety (since 2007)
Expert Review of Pharmacoeconomics and Research Outcomes
(since 2006)
Expert Review of Neurotherapeutics (since 2006)
Human Psychopharmacology (since 8/2009)
International Journal of Neuropsychopharmacology (since 2008)
International Journal of Sleep and Wakefulness (since 2008)
International Journal of Psychiatry in Medicine (since 3/2009)
Journal of Affective Disorders with Dr. Calabrese (since May
2008).
Journal of Clinical Psychiatry (since 2007)
Journal of Clinical Psychopharmacology (since March, 2008)
Journal of Psychiatric Research with Dr. Calabrese (since 2008)
Journal of Psychopharmacology with Dr. Calabrese (since 2008)
Lancet (with Calabrese since 7/2009)
Medical Science Monitor (since 11/2008)
Neuropsychiatric Disease and Treatment (since 2007)
Progress in Neuro-Psychopharmacology & Biological Psychiatry
(since 2007)
Psychiatry Research (since 2007)
Psychiatric Times (since 2007)

RESEARCH

National Institute of Mental Health

- 1. Lithium Use for Bipolar Disorder (LiTMUS): A Randomized Controlled Effectiveness Trial. Coordinating Multisite PI: Andrew A. Nierenberg, MGH, Harvard Medical School. CWRU Site PI – Joseph R Calabrese, M.D, Site Co-PI – Keming Gao, M.D., Ph.D. (10%)**

Source: NO1MH8001 for the NIMH Bipolar Trials Network (BTN)
Project Dates: 2/1/2008 – 12/30/2011
Total Award: \$598,054.

This proposed study will assess the effectiveness of lithium as a component of treatment as usual (TAU) in a generalizable group of patients with bipolar disorder.

- 2. Bipolar Disorder Across the Life Span (P20, Developing Center for Intervention and Services Research). PI – Joseph R Calabrese, M.D. and Robert Findling, M. D. Co-PI – Keming Gao, M.D., Ph.D. (10%)**

Source: NIMH P20 MH-66054
Project Dates: 9/1/2003 – 9/30/2008
Total Award: \$2,967,934.

The primary objective of this funding is to build and maintain a network of sites to conduct phenomenologic and clinical trials research that concurrently address the life cycle, including those at community mental health center, children and adolescents, and those currently abusing alcohol and/or drugs.

- 3. Acute Pharmacotherapy of Late Life Mania. Coordinating Multisite PI: Robert Young, MD. CWRU PI Martha Sajatovic, MD. CWRU Co-IP - Keming Gao, M.D., Ph.D. (5%).**

Source: NIMH ROI
Project Dates: 6/2003 – 6/2008
Total Award: \$1,382,500.

The first randomized, double-blind, controlled comparison of lithium and divalproex in elders with bipolar I manic, mixed, and hypomanic episodes, designed to test differences in side effects and benefits under dosing conditions relevant to geriatric practice. Hospitalized and ambulatory patients (n=306) aged 60 years or older will be studied for 9 weeks.

- 4. Combination Therapy in Rapid Cycling Bipolar Disorder (R21). PI - Joseph R. Calabrese, M.D., Co-IP - Keming Gao, M.D., Ph.D. (10%).**

Source: R21 (Exploratory/Development Grant) MH62650
Project Dates: 2/1/2002 – 1/31/2005
Total Award: \$573,750.

The primary objective of this study is to compare the efficacy of the tripple regimen lithium/divalproex/blinded lamotrigine to lithium/divalproex placebo in the acute and continuation treatment of patients with rapid cycling bipolar disorder over a six month randomized phase.

5. Double-blind, Longitudinal Evaluation of the Efficacy and Safety of the Combination of Lithium and Divalproex versus Lithium Monotherapy in Rapid Cycling Bipolar Patients Who ate Abusing Alcohol, Cannabis, and/or Cocaine (R01-S). PI - Joseph R. Calabrese, M.D. Co-PI - Keming Gao, MD, Ph.D. (10%).

Source: R-01 MH-50165 (Supplement)
Project Dates: 10/1/97 – 12/01
Total Award: \$674,938

The primary objective of this study is to compare the efficacy of the combination of lithium and divalproex as compared to lithium monotherapy in the prevention of episodes in patients with rapid cycling bipolar disorder who are currently abuse alcohol, cannabis, and/or cocaine over a six month randomized phase.

6. Systematic Treatment Enhancement Program (STEP) for Bipolar Disorder – A NIMH multicenter study designed to carry out a series of health effectiveness trials. Site PI - Joseph R. Calabrese, MD. Site Co-PI - Keming Gao, MD, Ph.D.

Source: MH-98-DS-001 (subcontract from Mass. Gen'l Hospital)
Project Dates: 8/99 – 3/2004
Total award: \$874,956

The primary objective of this study is to improve the treatment of bipolar disorder by 1) implementing model practice procedures across a network of clinicians, 2) determine the cost effective somatic and psychosocial intervention strategies for the depressed phase of the illness, 3) determine which interventions most effectively prevent relapse, 4) provide a systematic means of for the translation of novel treatments into clinicians practice, and 5) estimate the costs and quality of life outcomes in both acute and long-term setting.

Foundation

1. Quetiapine-XR Monotherapy in the Treatment of Major Depressive Disorder with Comorbid Generalized Anxiety Disorder: A Pilot Study. PI: Keming Gao, MD, PhD.

Source: Morley Family Foundation
Project Dates: 7/1/2008 – 6/30/2009
Total Award: \$10,000.

The primary objective is to evaluate the efficacy and safety of Quetiapine XR in the treatment of major depressive disorder comorbid generalized anxiety disorder.

2. **A Pragmatic Clinical Effectiveness Trial in Multi-morbid Anxious Patients with Bipolar I or II Depression - Focus on the Development of Novel Treatments –. PI: Keming Gao, M.D, Ph.D.**

Source: NARSAD
Project Dates: 7/1/2006 – 6/30/2008
Total Award: \$60,000.

The primary objective of this funding is to study the efficacy and safety of quetiapine in patients with bipolar depression and comorbid anxiety disorder with or without substance used disorder.

3. **Combination Therapy in Dual Diagnosis Rapid Cycling Bipolar Disorder (R21S). PI - Joseph R. Calabrese, M.D., Co-PI - Keming Gao, M.D., Ph.D. (10%).**

Source: Stanley Medical Research Institute
Project Dates: 7/02-7/05
Total Award: \$805,230.

The primary objective of this study is to compare the efficacy of the triple regimen lithium/divalproex/blinded lamotrigine to lithium/divalproex placebo in the acute and continuation treatment of patients with rapid cycling bipolar disorder who are currently abusing alcohol, cannabis, and/or cocaine over a six month randomized phase.

Industry – Funded Research

1. **Quetiapine-XR Monotherapy or Adjunctive Therapy in the Treatment of comorbid generalized anxiety in bipolar depression with or without substance use disorder: PI – Keming Gao, MD, PhD (10%).**

The primary objective is to evaluate the efficacy and safety of Quetiapine XR in the treatment of bipolar depression comorbid with generalized anxiety disorder with or without substance use disorder.

Source: AstraZeneca
Project Dates: 3/09 –3/11
Total award: \$418,990.00

2. **Quetiapine-XR Monotherapy in the Treatment of Major Depressive Disorder with Comorbid Generalized Anxiety Disorder. PI – Keming Gao, MD, PhD (10%).**

The primary objective is to evaluate the efficacy and safety of Quetiapine XR in the treatment of major depressive disorder comorbid generalized anxiety disorder.

Source: AstraZeneca
Project Dates: 12/07 – 12/09
Total award: \$399,562.50

3. **An 8-week, Double-Blind, Placebo-Controlled, Parallel Group, Fixed Dose Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I**

disorder. Site PI - Joseph R. Calabrese, M.D., Site Co-PI - Keming Gao, MD, PhD. (5%)

The primary objective is to evaluate the efficacy and safety of armodafinil adjunctive therapy in the treatment of patients with bipolar I depression.

Source: Cephalon
Project Dates: 9/07 – 05/08
Total award: \$?? per patient

- 4. A multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active controlled Study of the Efficacy and Safety of Sustained-release Quetiapine (SEROQUEL) Compared with Placebo in the Treatment of Generalized Anxiety Disorder (Gold Study). Site PI – Keming Gao, MD, PhD (10%). Site Co-PI – David E. Kemp, MD.**

The primary objective is to evaluate the efficacy of quetiapine fumarate (Seroquel) compared to placebo in the treatment of anxiety symptoms in patients with Generalized Anxiety Disorder.

Source: AstraZeneca
Project Dates: 10/06 – 07/07
Total award: \$8,000.00 per patient

- 5. A multicenter, Randomized, Parallel-group, Placebo-controlled, Double-blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) versus Placebo as Adjunctive Therapy with Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients with Bipolar I Disorder. Site PI – Margaret Kotz, MD. Site Co-PI – Keming Gao, MD, PhD (5%).**

The primary objective of this study is to evaluate the efficacy of quetiapine versus placebo when used as adjunctive therapy with lithium or divalproex in reducing the proportion of heavy drinking days from baseline to week 12 as derived from the Timeline Followback scale.

Source: AstraZeneca
Project Dates: 09/06 – 07/07
Total award: \$8,000.00 per patient

- 6. Double-Blind, Placebo-Controlled Divalproex Sodium-ER in Bipolar I or II Depression. PI - Joseph R. Calabrese, M.D., Co-PI - Keming Gao, MD, PhD. (10%)**

Source: Abbott Laboratories
Project Dates: 07/03 – 07/05
Total award: \$118,625

The primary objective of this study is to evaluate the efficacy and tolerability of Divalproex sodium-ER (Dvpx-ER) vs. placebo in the treatment of major depressive episodes in bipolar I and bipolar II previously misdiagnosed and treated as recurrent major depression. The secondary objectives are to evaluate the anxiolytic efficacy and tolerability of Dvpx-ER vs. placebo in this

population of previously undiagnosed bipolar depressives and to better characterize the clinical presentation of the misdiagnosed bipolar patient.

- 7. A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients with Bipolar I Depression. Site PI - Douglas McLaughlin, M.D., Co-PI - Keming Gao, M.D., Ph.D. (10%)**

Source: Pfizer
Project Dates: 10/05 – 05/06
Contract Amount: 5813.75 per patient

The primary objective of this study is to evaluate the efficacy and tolerability of Ziprasidone vs. placebo in the acute treatment of bipolar I depression.

- 8. Olanzapine in Treatment of Refractory Mania. Site PI - Joseph R. Calabrese, M.D., CO-PI – Keming Gao, M.D., Ph.D. (5%).**

Source: Lilly
Project Dates: 05/01 - 4/02
Contracted Amount: \$241,000

The primary objective of this study is to assess the efficacy and safety of olanzapine monotherapy in the acute treatment of refractory bipolar mania.

Manuscripts under Preparation:

Gao K, Kemp DE, Ganocy SJ, Calabrese JR. Association of Comorbid Anxiety or Substance Use Disorders with Previous Pharmacological Treatments in Rapid Cycling Bipolar Disorder

Gao K, Kemp DE, Ganocy SJ, Calabrese JR. Predictors of Hospitalization in Patients with Rapid Cycling Bipolar Disorder.

Manuscripts under Review:

Gao K, Kemp DE, Ganocy SJ, Conroy C, Findling RL, Calabrese JR. Anxiety Substance use disorders confound the clinical diagnosis of bipolar I disorder but not II. (submitted to IJCP on 07/16/2009)

Gao K, Kemp DE, Ganocy SJ, Calabrese JR Clinical and Methodological Considerations in Understanding Studies of Real World Patients with Bipolar Disorder. J Clinical Psychiatry (submitted on 2/4/2009, rejected on 3/2009).

Manuscripts under Revision:

Gao K, Verduin ML, Kemp DE, Tolliver B, Ganocy SJ, Bilali S, Brady KT, Findling RL, Calabrese JR. Correlates of Co-occurring Generalized Anxiety Disorder, Panic Disorder, and Obsessive Compulsive Disorder in Rapid Cycling Bipolar Disorders: Focus on Substance Use Disorder (submitted to American J on Addiction 06/12/2008, revision after review).

Manuscripts under Re-review:

Gao K, Kemp DE, Fein E, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder with atypical antipsychotics (Submitted to JCP on 7/15/2009)

Oral Presentations:

Local:

1. Effect of serotonin in the rostral ventrolateral medulla on the cardiovascular activities. Presented at the meeting required for Master Degree study, Department of Physiology, Shanghai Medical University, Shanghai, P. R. China, 1990.
2. Inhibitory effects of serotonin in the rostral ventrolateral medulla on pressor response and ventricular extrasystoles induced by hypothalamic stimulation. Presented at the dissertation for Master Degree, Department of Physiology, Shanghai Medical University, Shanghai, P. R. China, 1991.
3. Properties of the rostral ventrolateral medullary neurons. Presented at the meeting required for Ph.D. training, Department of Physiology, Shanghai Medical University, Shanghai, P. R. China, 1992.
4. Integrated responses of the rostral ventrolateral medullary neurons of the rat. Presented at the dissertation for Ph.D., Department of Physiology, Shanghai Medical University, Shanghai, P. R. China, 1994.
5. In vivo neuronal electrical activity recording techniques. Presented at a series of seminars of National Key Lab, Department of Neurobiology, Shanghai Medical University, Shanghai, P. R. China, 1994.
6. Raphe magnus serotonergic neurons do not mediate the analgesic effect induced by PAG stimulation. Presented at the Academic Meetings of Chinese Scholars at the University of Chicago, Chicago, IL, 1997.
7. Endogenous pain modulation systems: Basis and clinical implications. Presented at the Grand Rounds of the Department of Psychiatry at MetroHealth Medical Center, Cleveland, OH, 2004.

8. Typical and atypical antipsychotics in bipolar depression: Grand Rounds in the Department of Psychiatry at MetroHealth Medical Center, Cleveland, OH, 2005.
9. Typical and atypical antipsychotics in bipolar depression: Grand Rounds at the Northcoast Behavioral Health Systems, Northfield, OH, 2005.
10. Typical and atypical antipsychotics in bipolar depression: Grand Rounds in the Department of Psychiatry, University Hospitals of Cleveland/Case School of Medicine, OH, 2005.
11. Typical and atypical antipsychotics in bipolar depression: Grand Rounds in the Department of Psychiatry, Louis Stokes VA Medical Center, Brecksville, OH, 2005.
12. Can I diagnose depression by myself? Health education seminars at Chinese School of the Cleveland Chinese Contemporary Cultural Association, Solon, OH 2005.
13. New Development in Diagnosis and Treatment of Bipolar Disorder. Presented at the 8th All-Ohio Institute on Community Psychiatry; March 16, 2007; Beachwood, Ohio. No. S-9a.
14. Comorbid Anxiety in Bipolar Disorder: Phenomenology and Treatment Strategy. Grand Rounds in the Department of Psychiatry (7/20/2007), University Hospitals Case Medical Center/Case School of Medicine, Cleveland, Ohio.
15. Comorbid Anxiety in Bipolar Disorder: Phenomenology and Treatment Strategy. Grand Rounds in the Department of Psychiatry (10/18/2007), MetroHealth Medical Center, Cleveland, Ohio.
16. Treating mental illness in first and second generation Asian immigrants: the challenge. Presented at the Annual Meeting of Asian Pacific American Medical Student Association. Region V conference, Cleveland Ohio, 4/26/2008.
17. Major depression: manifestation and diagnosis. Education Lectures at Chinese School of the Cleveland Chinese Contemporary Cultural Association, Solon, OH (11/21/2008).
18. Mood Disorders and Anxiety: Phenomenology and Treatment Strategy presented Health Minds Across America a National Day of Free Public Forums on the Progress and Promise of Mental Health Research Sponsored by NARSAD, 29/14/2008, Cleveland, OH.
19. Comorbidity of Anxiety with Mood Disorders: Phenomenology and Treatment Challenge. Presented at the 9th All-Ohio Institute on Community Psychiatry; March 20-21, 2009; Beachwood, Ohio.

National/International

20. Effect of excitation of raphe nucleus obscurus on the changes of 5-HIAA in PGL. Presented at the Second Applied Physiology Symposium, Tanjin, P.R. China, 1990.
21. Intracellular recording of defense-reaction-related neurons in the PGL and effect of somatic inputs on intracellular recording of defense-reaction-related neurons in PGL. Presented at the First National Congress of Neuroscience, Shanghai, P. R. China, 1992.
22. Changes of the responsiveness of the neurons in the PGL during blood pressure altered. Presented at the First National Conference of the Young Chinese Physiologists, Beijing, P. R. China, 1993.
23. Inhibitory effect of 5-HT in the rostral ventrolateral medulla on pressure and ventricular extrasystoles induced by hypothalamic stimulation. Presented at the Third National Conference of the Published Excellent Papers of the Young Chinese Physiologist Sponsored by the Zhang Xijun Foundation of Chinese Association for Physiological Sciences, Beijing, P. R. China, 1993.
24. Factors influencing the excitability of neurons in PGL in anesthetized rats. Presented at the Symposium on Neurobiology for the neurobiologists from Mainland China, Taiwan, and Hong Kong, Shanghai, 1993.
25. Pain pathways, neurotransmitters, and receptors: From pain research to understand the tools for modern neuroscience. Visiting Professor Lecture at Weifang Medical University, Weifang City, Shandong Province, China, 2004.
26. Endogenous pain modulation: Basis and clinical practice. Visiting Professor Lecture at Weifang Medical University, Weifang City, Shandong Province, China, 2004.
27. Typical and atypical antipsychotics in bipolar depression. Clinical Report for the 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.
28. Thyroid response to lithium in bipolar rapid cyclers with or without a current substance use disorder. Presented at the American Psychiatric Association Research Colloquium for Junior Investigators, May 22, 2005, Atlanta, Georgia.
29. Comorbid anxiety in bipolar disorder: phenomenology and treatment strategy. Presented at the Second Annual Career Development Institute for Bipolar Disorder. April 29 – May 2, 2006, Roca Raton, Florida.

30. Associations of Comorbid Anxiety Disorder and Substance Use Disorder in Patients with Rapid Cycling Bipolar Disorder. Presented at the American Psychiatric Association Research Colloquium for Junior Investigators, May 21, 2006, Toronto, Ontario Canada.
31. Efficacy of the Antipsychotics in Anxiety Symptoms/Disorders with or without Bipolar disorder. Presented at the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. No. 48.
32. Achieving Wellness in Patients with Bipolar Disorder and Comorbid Anxiety: Guiding adult patients to wellness with comorbid mood and anxiety disorders (CME Outfitters Continuing Medical Education). Presented at the 27th Annual Meeting of Anxiety Disorders Association of America, March 29-April 1, 2007, St. Louis, MO.
33. In direct comparison of the safety and tolerability of antipsychotics in patients with bipolar disorder and schizophrenia. Presented at the 160th Annual Meeting of the American Psychiatric Association; May 19-24; 2007; San Diego, California.
34. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia. Presented at the 161th Annual Meeting of the American Psychiatric Association; May 3-8; 2008; Washington, DC.
35. Impact of excluding comorbid anxiety and substance abuse/dependence on generalizability of clinical trials in bipolar disorder. In Bipolar NCDEU New Investigator Awardee Panel: Balancing Generalizability and Assay Sensitivity in Bipolar Treatment Trials. Present at the 48th Annual NCDEU Meeting sponsored by National Institute of Mental Health and American Society of Clinical Psychopharmacology; May 27 – 30; 2008; Phoenix, Arizona.
36. Mood Disorders: Diagnosis, Treatment, and Research Opportunity. Visiting Professor Lecture at Weifang Medical University, Weifang City, Shandong Province, China, 2008.
37. How to get a manuscript published. Visiting Professor Lecture at Weifang Medical University, Weifang City, Shandong Province, China, 2008.
38. Comorbid Anxiety and Substance Use Disorder Confound the Clinical Diagnosis of Bipolar I But not II: Implications of Mood Stabilizer Use. Presented at the 162nd Annual Meeting of the American Psychiatric Association; May 16-21; 2009; San Francisco, CA.

PUBLICATIONS

Peer-Reviewed Papers:

1. Guo X, Gao K, Zhu D. Effect of microinjection of 5-HT into the rostral ventrolateral medulla on ventricular extrasystoles induced by hypothalamic stimulation in the rabbit. Chinese Journal of Physiological Sciences 1990; 6:129-137.

2. **Gao K**, Lin Y. Guo X. Changes of 5-hydroxyindoleacetic acid in the nucleus paragigantocellularis lateralis detected with *in vivo* voltammetry. Chinese J Physiological Sciences 1991; 7:27-33.
3. **Gao K**, Guo X. Serotonergic mechanism in the rostral ventrolateral medulla plays a role in the inhibitory effect of somatic inputs on the experimental ventricular extrasystoles. Chinese J of Physiological Sciences 1991; 7 300-308.
4. **Gao K**, Li P. Post-synaptic activity evoked in the rostral ventrolateral medullary neurons by stimulation of the defense areas of hypothalamus and midbrain in the rat. Neuroscience Letters 1993; 161:153-156.
5. **Gao K**, Li P. Convergent inputs to the rostral ventrolateral medullary neurons of the rat. Chinese J Physiological Sciences 1993; 9:372-376.
6. **Gao K**, Li P. Effects of baroreceptor inputs on the activity of rostral ventrolateral medullary neurons evoked by stimulation of defense areas and somatic nerves. Chinese J Physiological Sciences 1994; 10:283-288.
7. **Gao K**, Li P. Responses of neurons in the nucleus paragigantocellularis lateralis to somatic nerve stimulation, Neuroscience Letters 1994; 178:15-18.
8. **Gao K**, Li P. Integrated responses of the rostral ventrolateral medullary neurons to the stimulation of the defense area of hypothalamus or midbrain and somatic nerves, Acta Academiae Medicinae Shanghai 1994; 21 (Suppl):20-25.
9. **Gao K**, Kim YH, Mason P. Serotonergic pontomedullary neurons are not activated by antinociceptive stimulation in the periaqueductal gray. J Neuroscience 1997; 17: 3285-3292.
10. **Gao K**, Mason P. Somatodendritic and axonal anatomy of intracellularly labeled serotonergic neurons in the rat medulla. J Comparative Neurology 1997; 389:309-328.
11. **Gao K**, Chen DO, Genzen JR, Mason P. Activation of serotonergic neurons in the raphe magnus is not necessary for morphine analgesia. J Neuroscience 1998; 18:1860-1864.
12. Mason P, **Gao K**. Raphe magnus serotonergic neurons tonically modulate nociceptive transmission. Pain Forum 1998; 7:143-150.
13. Mason P, **Gao K**. The identification of serotonergic neurons: *in vivo* versus *in vitro*, Pain Forum 1998; 7:163-166.
14. **Gao K**, Mason P. Serotonergic raphe magnus cells that respond to noxious tail heat are not ON or OFF cells. J Neurophysiology 2000; 84:1719 -1725.

15. **Gao K**, Mason P. The discharge of a subset of serotonergic raphe magnucells is influenced by baroreceptor input. *Brain Research* 2001; 900:306 - 313.
16. **Gao K**, Mason P. Physiological and anatomical evidence for functional subclasses of serotonergic raphe magnus cells. *J Comparative Neurology* 2001; 439:426 - 439.
17. Mason P, **Gao K**, Genzen J. Serotonergic raphe magnus cell discharge reflects on-going autonomic and respiratory activities. *J. Neurophysiology* 2007; 98:1919-1927.

During- and Post-Bipolar Research Fellowship Era:

18. Gajwani P, Forsthoff A, Muzina D, Amann B, **Gao K**, Elhaj O, Shelton MD, Calabrese JR, and Grunze H. Antiepileptic drugs in mood disordered patients. *Epilepsia*. 2005; 46 Suppl 4:38-44.
19. Muzina DJ, Elhaj O, Gajwani P, **Gao K**, Shelton MD, Calabrese JR. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. *Acta Psychiatr Scand Suppl*, 2005; 426:21-28.
20. **Gao K.**, Gajwani P., Elhaj O. and Calabrese JR. Typical and Atypical Antipsychotics in Bipolar Depression. *J Clin Psychiatry* 2005; 66: 1376-1385.
21. **Gao K**, Calabrese JR. Newer treatment studies for bipolar depression. *Bipolar Disorders* 2005; 7 (Suppl. 5):13-23.
22. Gajwani P, Muzina DJ, **Gao, K**, Calabrese JR. Awareness under Anesthesia during ECT treatment. *J ECT* 2006 Jun; 22(2):158-159.
23. Muzina DE, Gajwani P, Kemp DE, **Gao K**, Calabrese, JR. Antiepileptic Drugs for Acute Bipolar Depression: Applying Data to Clinical Practice. *Psychiatric Annals* 2006, 36:637-644.
24. Muzina DE, Kemp DE, **Gao K**, Gajwani P, Calabrese, JR. Atypical Antipsychotics in Bipolar Depression: Applying Emerging Evidence to Clinical Practice. *Psychiatric Annals* 2006, 36:646-652.
25. **Gao K**, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. *J Clin Psychiatry* 2006; 67:1327-1340.
26. **Gao K**, Gajwani P, Muzina D, Abraham P, Xia G, Calabrese JR. The effects of antipsychotics on mood. *Adv Schizophr Clin Psychiatry* 2006; 2(4):120-127.
27. Kemp DE, **Gao K**, Muzina DJ, Calabrese JR. Progress in the Treatment of Bipolar Depression: Advances and Challenges. *Psychiatric Times* 2006; 553 (9):39-44).

28. **Gao K.** Antipsychotics in the treatment of comorbid Anxiety in bipolar disorder. *Psychiatric Times* 2007, 24 (5):68-69.
29. Gajwani P, Muzina DJ, Kemp DE, **Gao K**, Calabrese JR. Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. *Neuropsychiatric Disease and Treatment* 2007, 3 (6):online.
30. Xia G, Gajwani P, Muzina DJ, Kemp DE, **Gao K**, Ganocy SJ, Calabrese JR. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. *Int J Neuropsychopharmacol* 2008;11(1):119-30.
31. **Gao K**, Ganocy SJ, Gajwani P, Muzina DJ, Calabrese JR. A Review of Sensitivity and Tolerability of Antipsychotics in Patients with Bipolar Disorder or Schizophrenia: Focus on Somnolence. *J Clin Psychiatry* 2008; 69:302-309.
32. **Gao K**, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia *J Clin Psychopharmacol* 2008; 28(2):203-209
33. **Gao K**, Verduin ML, Kemp DE, Tolliver B, Ganocy SJ, Elhaj O, Brady K, Findling RL, Calabrese JR. Clinical Correlates of Patients With Rapid-Cycling Bipolar Disorder and a Recent History of Substance Use Disorder: A Subtype Comparison From Baseline Data of 2 Randomized, Placebo-Controlled Trials. *J Clin Psychiatry* 2008; 69(7):1057-63.
34. **Gao K**, Tolliver B, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady K, Shim SS, Findling RL, Calabrese JR. Differential Interactions between Comorbid Anxiety and Substance Use Disorder in Rapid Cycling Bipolar I or II Disorder. *J Affect Disord.* 2008; 110 (1-2):167-173.
35. **Gao K**, Kemp D, Ganocy SJ, Muzina D, Xia G, Findling R, Calabrese JR. Treatment-emergent mania/hypomania during antidepressant monotherapy in bipolar disorder rapid cycling bipolar disorder. *Bipolar disorders* 2008; 10 (8):907-915.
36. Kemp DE, **Gao K**, Ganocy SJ, Rapport DJ, Elhaj O, Bilali S, Conroy BA, Findling RL, Calabrese JR. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid cycling bipolar disorder comorbid with substance abuse or dependence *J Clin Psychiatry* 2009 Jan;70(1):113-121.
37. Kemp DE, **Gao K**, Ganocy SJ, Caldes E, Feldman K, Chan PK, Conroy C, Bilali S, Findling RL, Calabrese JR. Medical and Substance Use Comorbidity in Bipolar Disorder. *Journal of Affective Disorders*, 2009 Jul;116(1-2):64-69.
38. **Gao K**, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KT, Findling RL, Calabrese JR. Correlates of Historical Suicide Attempt in Rapid Cycling Bipolar

- Disorder: A Cross-sectional Assessment. *J Clin Psychiatry* 2009 Jul; 70 (7):1032 - 1040.
39. **Gao K**, Sheehan DV, Calabrese JR. Atypical Antipsychotics in Primary Generalized Anxiety Disorder or Comorbid with Mood Disorders. *Expert Review of Neurotherapeutics*. 2009 Aug;9(8):1147-58.

Book Chapters:

40. Muzina DJ, Elhaj O, Gajwani P, **Gao K**, Calabrese JR. Treatment of Rapid Cycling Bipolar Disorders. In: *Review of Psychiatry, Volume 24*. Series Editors: Oldham JM, Riba MB, *Advances in Treatment of Bipolar Disorders*. Ketter TA (ed). Washington, DC. American Psychiatric Press, 2005. Pages 165-198.
41. Calabrese JR, Shelton MD, **Gao K**, Gajwani P, Elhaj O. 'Lamotrigine'. In. 2nd Edition of *Essentials of Clinical Psychopharmacology*. Editors: Schatzberg and Nemeroff. Washington, DC. American Psychiatric Press, 2006. Pages 403-412.
42. Kemp DE, **Gao K**, Muzina DJ, Gajwani P, Calabrese JR. Trial-Based Advances in the treatment of bipolar depression. *Progress in Neurotherapeutics and Neuropsychopharmacology*. Editor: Jeffrey L. Cummings. Cambridge, United Kingdom. Cambridge University Press, 2007. Volume 2, Pages 193 – 211.
43. Kemp DE, Muzina DJ, **Gao K**, Calabrese JR. Lamotrigine. In: *Textbook of Psychopharmacology* (A. F. Schatzberg and C. B. Nemeroff, Eds.) (in press).
44. Kemp DE, **Gao K**, Calabrese JR. Anticonvulsants as agents for unmet need: focus on bipolar depression and rapid cycling. In *Antiepileptic Drugs to Treat Psychiatric Disorders, Medical Psychiatric Series/39*. Editors. McElroy SL, Keck Jr PE, and Post RM. Informa Healthcare, 2008. Pages 155-176.
45. **Gao K**, Kemp DE, Calabrese JR. Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In: *Milestones in Drug Therapy series* (M Parnham, J Bruinvels, series eds), *Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy*. (CA Zarate Jr, HK Manji, eds). Birkhauser Verlag AG, Switzerland, Springer Science + Business Media 2009, page 159 – 179.

Invited Non-Peer Reviewed Articles:

46. Calabrese JR, Shelton MD, Elhaj O, Gajwani P, **Gao K**. Clinical highlights in bipolar depression: focus on atypical antipsychotics. *J Clin Psychiatry* 2005; (Supp. 5):26-33.

47. Gajwani P, Kemp DE, Muzina DJ, Xia G, **Gao K**, Calabrese JR. Acute Treatment of Mania: An Update on New Medications. *Current Psychiatry Reports* 2006; 8:504-509.
48. Kemp DE, Muzina DJ, **Gao K**, Calabrese JR. Pharmacological treatments for bipolar depression: focus on atypical antipsychotics. *Directions in Psychiatry* 2007; 27:99-111.

Published Letters and Abstracts/Posters

1. **Gao K**, Lin Y, Guo X. Effect of excitation of raphe nucleus obscurus on the changes of 5-hydroxyindoleacetic acid (5-HIAA) in nucleus paragigantocellularis lateralis. *Chinese Association for Physiological Sciences (CAPS) News Communication* 1990; Suppl 1: 84-85 (in Chinese).
2. **Gao K**, Lin Y, Guo X., 5-hydroxyindoleacetic acid (5-HIAA) in nucleus paragigantocellularis lateralis detected with differential pulse voltammetry *in vivo*. *CAPS New Communication* 1991; 10 (Suppl 6):26 (in Chinese with English title).
3. **Gao K**, Li P. Intracellular recording of defense-reaction-related neurons in nucleus paragigantocellularis lateralis. *CAPS News Communication* 1992; 3 (Suppl 11):152 (in Chinese with English title).
4. **Gao K**, Li P. Effect of somatic inputs on intracellular recording of the defense-reaction-related neurones in the nucleus paragigantocellularis lateralis, *CAPS News Communication* 1992; 3 (Suppl 11):152 (in Chinese with English title).
5. **Gao K**, Li P. Changes of the responsiveness of the neurons in the nucleus paragigantocellularis lateralis during blood pressure altered. *CAPS News Communication* 1993; 12 (Suppl 2):39 (in Chinese).
6. **Gao K**. Inhibitory effect of 5-HT in the rostral ventrolateral medulla on pressor response and ventricular extrasystoles induced by hypothalamic stimulation, *CAPS News Communication* 1993; 12 (Suppl 2):66-67 (in Chinese).
7. **Gao K**, Li P. Summated responses of the rostral ventrolateral medullary neurons to the stimulation of ventromedial area of fornix (VAF) and dorsal periaqueduct gray matter (dPAG). *CAPS News Communication* 1993; Suppl:92-93 (in Chinese).
8. **Gao K**, Li P. Inhibitory phenomenon in the activity of rostral ventrolateral medullary neurones induced by stimulation of the defense areas and somatic nerves. *CAPS News Communication* 1993; Suppl:93 (in Chinese).
9. Li P, **Gao K**, Li J. Integrative function of the rostral ventrolateral medullary (rVLM) neurones under different blood pressure, In abstracts of XXXII Congress

- of the International Union of Physiological Sciences 1993; P234, Glasgow, Scotland.
10. Li P, Zhu DN, **Gao K**. Factors influencing the excitability of neurons in nucleus paragigantocellularis lateralis (PGL) in anesthetized rats. *Neurosci Lett* 1994; 45 Suppl:S10.
 11. Li P, Zhu D, **Gao K**. The role of ACh and corticoids in rostral ventrolateral medulla (rVLM) in stress induced hypertensive rats, In abstracts of the Third Congress of Federation of Asian and Oceanian Physiological Societies, Shanghai, China, 1994, p53.
 12. Genzen JR, **Gao K**, Chen DO, Mason P. Participation of pontomedullary serotonergic neurons in cardiovascular modulation. *Society for Neuroscience Abstract* 1997; 23:157.
 13. **Gao K**, Mason P. Participation of raphe magnus ON and OFF cells in cardiovascular modulation. *Society for Neuroscience Abstract* 1997; 23:157.
 14. **Gao K**, Mason P. Anatomical and physiological evidence for functional subclasses of serotonergic cells in the medullary raphe magnus of the rat, *Society for Neuroscience Abstract* 1999; 25:1674.
 15. Mason P. and **Gao K**. Effect of periaqueductal gray activation on serotonergic cells in the medullary raphe magnus of the rat. *Society for Neuroscience Abstract* 1999; 25:1674.

During- and Post-Bipolar Research Fellowship Era:

16. **Gao K**, Elhaj O, Gajwani P, Calabrese JR. Comorbid anxiety and substance use disorders in bipolar patients with rapid cycling. In: *Syllabus and Proceeding Summary of the 7th All-Ohio Institute on Community Psychiatry*; March 18-19, 2005, Beachwood, Ohio.
17. **Gao, K** and Calabrese JR. Typical and atypical antipsychotics in bipolar depression. In: *Syllabus and Proceeding Summary of the 158th Annual Meeting of the American Psychiatric Association*; May 21-26, 2005; Atlanta, GA. No. 96.
18. **Gao K**, Elhaj O, Shelton, MD, Youngstrom E, Findling R, Calabrese, JR. Patterns of comorbid substance use disorder in bipolar rapid cyclers. In: *New Research Abstracts of the 158th Annual Meeting of the American Psychiatric Association*; May 21-26, 2005; Atlanta, GA. NR 92.
19. **Gao K**, Elhaj O, Gajwani P, Calabrese JR. Comorbid anxiety disorders in bipolar rapid cyclers with or without a dual diagnosis. In: *the 45th Annual NCDEU Meeting*, June 6-9, 2005, Boca Raton, Florida. Session - II, 57.

20. **Gao K**, Elhaj O, Gajwani P, Shelton MD, Youngstrom EA, Bilali S, Slembariski R, Findling RL, Calabrese JR. Psychosis in bipolar patients with rapid cycling. *Bipolar Disorders* 2005; 7 (Suppl. 2):57.
21. Muzina DJ, Shelton MD, Elhaj O, Gajwani P, **Gao, K**, Youngstrom E, Bilali S, Calabrese JR. Impact of misdiagnosis in dual diagnosis rapid cycling bipolar disorder. *Bipolar Disorders* 2005; 7 (Suppl. 2):81.
22. **Gao K**, Calabrese JR. Efficacy of the Antipsychotics in Anxiety Symptoms/Disorders with or without Bipolar disorder. In: Syllabus and Proceeding Summary of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. No. 48.
23. **Gao K**, Ganocy SJ, Bilali S, Conroy C, Calabrese JR. Pragmatic consideration in the comorbid presentations of anxiety disorder and substance use disorder in patients with rapid cycling bipolar disorder. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. NR 51.
24. **Gao K**, Conroy C, Bilali S, Ganocy SJ, Elhaj O, Calabrese JR. Differences between patients with rapid cycling bipolar I and II disorders in comorbid anxiety disorder and substance use disorder. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. NR 784.
25. **Gao K**, Bilali S, Conroy C, Ganocy SJ, Elhaj O, Calabrese JR. Clinical impacts of comorbid anxiety disorder and substance use disorder on patients with rapid cycling bipolar disorder. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. NR 217.
26. Ganocy SJ, Calabrese JR, Elhaj O, **Gao K**, Bilali S, Conroy C. Predictors of legal involvement in patients with dual diagnosis rapid cycling bipolar disorder. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada. NR 216.
27. Kemp DE, **Gao K**, Ganocy SJ, Bilali S, Conroy C, Calabrese JR. Lithium monotherapy versus the combination of lithium and divalproex for rapid cycling bipolar disorder comorbid with substance abuse or dependence: A 6-month, double-blind maintenance trial. *Neuropsychopharmacology* 2006; 31(S1):S106.
28. **Gao K**, Kemp DE, Ganocy SJ, Calabrese JR. Independent predictor of suicide attempt in patients with rapid cycling bipolar disorder. In: Syllabus and Proceeding Summary of the 8th All-Ohio Institute on Community Psychiatry; March 15-16, 2007, Beachwood, Ohio.
29. **Gao K**, Ganocy SJ, Calabrese JR. Indirect comparison of the safety and tolerability of antipsychotics in patients with bipolar disorder and schizophrenia.

- In: Syllabus and Proceeding Summary of the 160th Annual Meeting of the American Psychiatric Association; May 19-24; 2007; San Diego, California. No. 69.
30. Kemp DE, Ganocy SJ, **Gao K**, Elhaj O, Rapport D, Bilali S, Calabrese JR. A 6-month, pilot, double-blind, maintenance trial of Lithium monotherapy versus the combination of lithium and divalproex for dual diagnosis rapid cycling bipolar disorder. In: New Research Abstracts of the 160th Annual Meeting of the American Psychiatric Association; May 19-24; 2007; San Diego, California. NR. 16.
 31. **Gao K**, Ganocy SJ, Kemp DE, Elhaj O, Calabrese JR. Predictors of hospitalization and suicide attempt in patients with rapid cycling bipolar disorder. In: New Research Abstracts of the 160th Annual Meeting of the American Psychiatric Association; May 19-24; 2007; San Diego, California. NR. 94.
 32. Caldes E, Kemp D, Ganocy S, Elhaj O, Shelton M, Conroy C, Bilali S, Bachtel MB, Pontau J, **Gao K**, Calabrese JR. Profiles of the addiction severity index (ASI) subscale scores and their relationship to treatment response with lithium and divalproex in dual diagnosis bipolar disorder. *Bipolar Disorders* 2007; 9 (Suppl 1):26
 33. Conroy C, Muzina DJ, Ganocy S, **Gao K**, Kemp D, Elhaj O, Bilali S, Bachtel MB, Slembariski R, Pontau J, Caldes E, Calabrese JR. Spectrum of legal offences by gender in a large sample of bipolar disorder. *Bipolar Disorders* 2007; 9 (Suppl 1):29
 34. **Gao K**, Kemp DE, Xia G, Ganocy SJ, Muzina DJ, Bilali S, Conroy C, Calabrese JR. Treatment-emergent mania/hypomania during second-generation antidepressant monotherapy in patients with rapid cycling bipolar disorder. *Bipolar Disorders* 2007; 9 (Suppl 1):41-42.
 35. Muzina DJ, **Gao K**, Kemp D, Ganocy S, Bilali S, Conroy C, Bachtel MB, Pontau J, Caldes E, Calabrese JR. Legal complications of rapid cycling bipolar disorder accompanied by recent substance use disorders. *Bipolar Disorders* 2007; 9 (Suppl 1):81.
 36. Slembariski R, **Gao K**, Ganocy SJ, Elhaj O, Conroy C, Bilali S, Bachtel MS, Pontau JR, Caldes E, Kemp DE, Calabrese JR. Spectrum of legal offenses associated with rapid cycling bipolar disorder with and without a recent history of a substance use disorder. *Bipolar Disorders* 2007; 9 (Suppl 1):98.
 37. **Gao K**, Conroy C, Slembariski R, Pontau JR, Bachtel MS, Bilali S, Caldes E, Kemp DE, Elhaj O, Ganocy SJ, Calabrese JR. Lifetime exposure to psychotropic medications in rapid cycling I or II disorder with and without comorbid anxiety disorder. *Bipolar Disorders* 2007; 9 (Suppl 1):116.

38. **Gao K**, Calabrese JR, Ganocy SJ. Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia. In: Syllabus and Proceeding Summary of the 161th Annual Meeting of the American Psychiatric Association; May 3-8; 2008; Washington DC. No. 57.
39. **Gao K**, Kemp DE, Calabrese JR. Recent substance use disorder, not generalized anxiety disorder, intensifies lithium-induced TSH increase in rapid cycling bipolar disorder. In: New Research Abstracts of the 161th Annual Meeting of the American Psychiatric Association; May 3-8; 2008; Washington DC. NR1-051.
40. Muzina DJ, Khalife S, **Gao K**, Kemp DE, Ganocy SJ, Bachtel MB, Colangelo E, Conroy C, Bilali S, Calabrese JR. A double-blind, placebo-controlled study of divalproex-ER in newly diagnosed mood stabilizer naïve patients with acute bipolar depression. In: New Research Abstracts of the 161th Annual Meeting of the American Psychiatric Association; May 3-8; 2008; Washington DC. NR3-028.
41. **Gao K**, Ganocy SJ, Calabrese JR. Anxiety and substance use disorder in rapid cycling bipolar disorder: prevalence and their associations with previous pharmacotherapy. In the Abstract of the 10th Annual Future Leaders in Psychiatry sponsored by Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences; May 22-25, 2008; Orlando, Florida.
42. Gao K. Impact of excluding comorbid anxiety and substance abuse/dependence on generalizability of clinical trials in bipolar disorder. In Program Session Abstracts of the 48th Annual NCDEU Meeting, May 27 – 30; 2008; Phoenix, Arizona. P121.
43. **Gao K**, Kemp DE, Ganocy SJ, Calabrese JR. Lifetime Treatment-Emergent Mania during Antidepressant Monotherapy Trials in Patients with Current Rapid Cycling Bipolar Disorder. In: Syllabus and Proceeding Summary of the 9th All-Ohio Institute on Community Psychiatry; March 20-21, 2009, Beachwood, Ohio.
44. **Gao K**, Kemp DE, Ganocy SJ, Calabrese JR. The Sensitivity and Tolerability of Quetiapine-XR in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder. In: New Research Abstracts of the 162nd Annual Meeting of the American Psychiatric Association; May 16-21; 2009; San Francisco, CA. NR4-050.
45. **Gao K**, Kemp DE, Ganocy SJ, Conroy C, Calabrese JR. Comorbid Anxiety and Substance Use Disorder Confound the Clinical Diagnosis of Bipolar I But not II: Implications of Mood Stabilizer Use. In: the CME Syllabus and Proceedings Summary of the 162nd Annual Meeting of the American Psychiatric Association; May 16-21; 2009; San Francisco, CA.

46. **Gao K**, Kemp DE, Ganocy SJ, Conroy C, Serrano MB, Slembariski R, Calábrese JR. Predictors of Non-Randomization with Open-Label Lithium and Divalproex Treatment in Rapid Cycling Bipolar Disorder: a Post-hoc Analysis. *Bipolar Disorders* 2009; 11 (Suppl 1):
47. **Gao K**, Kemp DE, Ganocy SJ, Conroy C, Calabrese JR. The Sensitivity and Tolerability of Quetiapine-XR in the Treatment of Schizophrenia, Mania, Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder. In: the Abstracts of 45th Annual NCDEU Meeting, June 29-July 2, 2009, Hollywood, Florida.